GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$52.29
-0.49 (-0.93%)
▼
5d:
-1.51%
30d:
+2.19%
90d:
-10.17%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 28, 2026
13d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$66.45
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$41.26
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $52.29, which is considered fair relative to its 30-day fair value range of $51.24 to $52.91. The stock's valuation (Forward PE: 10.8) is in line with its historical norms (10.5). At these levels, the market is pricing in 1.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GSK is in a downtrend. The price is currently testing key support at $51.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GSK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GSK is in a downtrend. The price is currently testing key support at $51.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GSK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$51.24 -
$52.91
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($56.75)
- NEUTRAL: Market pricing in 1.0% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$51.24 -
$52.91
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$51.08
Resistance Level
$54.29
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.82
Wall Street Target
$56.75
(+8.5%)
Revenue Growth (YoY)
1.5%
Earnings Growth (YoY)
8.4%
Profit Margin
17.8%
Valuation Premium vs History
+1.0% premium
PE vs Historical
10.8 vs 10.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.0%
(market-implied from PE analysis)
1-Year Target
$52.81
(+1%)
2-Year Target
$53.34
(+2%)
3-Year Target
$53.87
(+3%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
PE COMPRESSION
$52.27
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 7.1%)
$129.43
(+148%)
Base:
(SPY PE: 10.8, Growth: 7.1%)
$64.31
(+23%)
Bear:
(PE: 9.2, Growth: 7.1%)
$54.67
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 14.07 | Current EPS (TTM): $3.75
Bull Case
$74.81
(+43%)
Analyst growth 28.8%, PE expands to 15.5
Base Case
$68.00
(+30%)
Market implied 28.8%, PE stable at 14.1
Bear Case
$35.89
(-31%)
Severe decline -20.0%, PE contracts to 12.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 5:18 AM ET
Data refreshes hourly during market hours. Next update: 6:18 AM
Data refreshes hourly during market hours. Next update: 6:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1240 | 58 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 64 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$263 | 59 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$223 | 59 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$356 | 56 HOLD |
